Exemestane reduces risk of breast cancer in high-risk, postmenopausal women

[News]

Today's major announcement at the American Society of Clinical Oncology annual meeting that the drug exemestane significantly reduces the risk of breast cancer in high-risk, postmenopausal women is the result of an international, randomized double-blind phase III clinical trial in which University at Buffalo researchers and hundreds of Western New York women played a critical role.

More... (http://www.news-medical.net/news/20110606/Exemestane-reduces-risk-of-breast-cancer-in-high-risk-postmenopausal-women.aspx)